ASX:IMMBiotechs
Immutep (ASX:IMM): Valuation Check After Dr. Reddy’s Licensing Deal and New Phase II Breast Cancer Data
Immutep (ASX:IMM) has jumped onto investors radar after two meaningful updates: a lucrative licensing deal with Dr. Reddy’s for its cancer immunotherapy efti, and fresh Phase II breast cancer data reinforcing its development pathway.
See our latest analysis for Immutep.
The recent licensing deal and upbeat breast cancer data appear to have flipped sentiment, with a 1 month share price return of 25.49 percent and a 90 day share price return of 36.17 percent standing in contrast to a still...